Table 2.
Baseline Clinical and Laboratory Investigations by Treatment Arm
| Characteristic | Acetaminophen (n = 31) | Control (n = 31) |
|---|---|---|
| Clinical examination | ||
| Temperature (°C) | 39.0 (37.2–40.0) | 38.9 (37.5–39.5) |
| Blood pressure (mmHg) | ||
| Systolic | 108 (100–116) | 110 (95–119) |
| Diastolic | 61 (50–70) | 69 (59–75) |
| Glasgow coma score | 15 (9–15) | 12 (9–15) |
| Respiratory rate (breaths/minute) | 30 (24–38) | 30 (28–40) |
| Heart rate (beats/minute) | 107 (96–118) | 108 (92–130) |
| Laboratory investigations | ||
| Parasite count per μLa | 53426 (24596–116048) | 17258 (5751–51785) |
| Plasma Plasmodium falciparum histidine rich protein 2 (mg/mL) | 1356 (146–4486) | 1308 (154–4961) |
| Sodium (mmol/L) | 134 (130–138) | 135 (130–138) |
| Potassium (mmol/L) | 3.5 (3.3–4.0) | 3.4 (3.0–3.9) |
| Chloride (mmol/L) | 103 (99–107) | 104 (100–107) |
| Glucose (mmol/L) | 5.8 (4.7–8.1) | 6.8 (5.5–9.0) |
| Blood urea nitrogen (mg/dL) | 23 (13–36) | 25 (16–43) |
| Creatinine (μmol/L) | 106 (97–169) | 115 (97–168) |
| Hemoglobin (g/dL) | 10.1 (8.0–12.7) | 11.6 (10.0–13.4) |
| Cell-free hemoglobin (ng/mL) | 42800 (16800–94100) | 52500 (23400–188800) |
| F2-isoprostanes (pg/mL) | 22.0 (14.5–27.7) | 23.6 (15.7–38.6) |
| Isofurans (pg/mL) | 44.7 (25.0–64.2) | 44.0 (26.1–84.0) |
| Total bilirubin (mg/dL)a | 1.5 (1.0–2.2) | 1.7 (1.2–2.4) |
| Indirect bilirubin (mg/dL)a | 0.7 (0.5–0.9) | 0.8 (0.6–1.2) |
| Lactate (mmol/L) | 2.89 (1.94–3.70) | 2.11 (1.62–4.84) |
| Bicarbonate (mmol/L) | 19.2 (17.3–21.8) | 18.5 (15.8–19.9) |
| Base excess (mmol/L) | -5 (-7–-3) | -7 (-10–-3) |
Data are median (interquartile range), unless otherwise indicated by a geometric mean (95% confidence interval). There were no significant differences between treatment groups in any of the measured baseline characteristics.